<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="67209">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02008539</url>
  </required_header>
  <id_info>
    <org_study_id>MSC_apceth_101/1</org_study_id>
    <nct_id>NCT02008539</nct_id>
  </id_info>
  <brief_title>Treatment of Advanced Gastrointestinal Cancer in a Phase I/II Trial With Modified Autologous MSC_apceth_101</brief_title>
  <acronym>TREAT-ME 1</acronym>
  <official_title>Treatment of Advanced Gastrointestinal Cancer in a Phase I/II Trial With Modified Autologous MSC_apceth_101</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Apceth GmbH &amp; Co. KG</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Apceth GmbH &amp; Co. KG</source>
  <oversight_info>
    <authority>Germany: Paul-Ehrlich-Institut</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To evaluate the safety and tolerability of MSC_apceth_101.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>October 2013</start_date>
  <primary_completion_date type="Anticipated">October 2016</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design>Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Safety and tolerability as indicated by Common Toxicity Criteria (CTC-AE) of the National Cancer Institute</measure>
    <time_frame>day 56 (+/- 7) in patient group 1 and day 29 (+/-3) in patient group 2</time_frame>
    <safety_issue>Yes</safety_issue>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">22</enrollment>
  <condition>Advanced Gastrointestinal Cancer</condition>
  <arm_group>
    <arm_group_label>treatment arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>MSC_apceth_101</intervention_name>
    <arm_group_label>treatment arm</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients with advanced or recurrent or metastatic gastrointestinal adenocarcinoma.

          -  Premature or scheduled termination of standard therapy

          -  Progressive disease as clinically assessed by the investigator

          -  Max. tumour lesion ≤ 5 cm

          -  Adequate organ function

          -  Ability of patient to understand character and individual consequences of clinical
             trial

          -  Age ≥ 18 years

          -  Written informed consent must be available before any study specific procedure is
             performed

        Exclusion Criteria:

          -  Patients with severe heart diseases

          -  Clinical significant ischemic disease during the last 4 weeks before Visit 1

          -  Severe lung disease

          -  Symptomatic peritoneal carcinomatosis

          -  Symptomatic pleural or pericardial effusion

          -  Serious uncontrolled acute infections less than 3 weeks before Visit 1

          -  Known dependency on alcohol or other drugs

          -  Patients requiring corticoids in doses above the Cushing threshold

          -  Known liver fibrosis or liver cirrhosis

          -  Any concomitant severe disease which could compromise the objectives of this study in
             the judgment of the investigator

          -  Female patient who is pregnant or breast feeding

          -  Participation in another clinical trial or observation period, respectively, during
             the last 4 weeks prior to the first IMP dose
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>apceth GmbH &amp; Co.KG</last_name>
    <phone>+49 89 7009608</phone>
    <phone_ext>0</phone_ext>
    <email>info@apceth.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>University Hospital Munich</name>
      <address>
        <city>Munich</city>
        <zip>81377</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>December 2013</verification_date>
  <lastchanged_date>December 6, 2013</lastchanged_date>
  <firstreceived_date>October 28, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Gastrointestinal Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
